Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03546803 · ClinicalTrials.gov registry record

3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis

A clinical trial of Radiation Dermatitis, sponsored by Mayo Clinic.

Completed
Registry status
14
Enrollment target
1
Study location

NCT03546803: Completed study of Radiation Dermatitis, sponsored by Mayo Clinic.

NCT03546803 is a study of Radiation Dermatitis that has completed, run by Mayo Clinic. The registered enrollment target is 14 participants, below the 48-participant average among 5 other Radiation Dermatitis trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03546803, a study of Radiation Dermatitis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
14 participants
Enrollment target
1
Study location

Study Summary

This study observes a liquid skin protectant that is a polymeric-cyanoacrylate solution designed to protect intact or damaged skin due to radiation.

Primary Outcome

To compare radiation dermatitis severity in irradiated skin protected by a liquid skin protectant (3M™ Cavilon™ Advanced Skin Protectant) that rapidly dries versus uncovered skin (internal control) as determined by a panel.

Conditions Studied

Interventions

  • OTHER 3M™ Cavilon™ Advanced Skin Protectant

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2018-02-19
Est. Completion 2019-08-12
Mayo Clinic

2,844 total trials

What the finished NCT03546803 record still lists

NCT03546803 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 48-participant average among 5 other Radiation Dermatitis trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Radiation Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which 3M™ Cavilon™ Advanced Skin Protectant is the first listed.

NCT03546803 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03546803 about?

NCT03546803 is a clinical study titled "3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis". This study observes a liquid skin protectant that is a polymeric-cyanoacrylate solution designed to protect intact or damaged skin due to radiation.

What is the current status of trial NCT03546803?

This trial is currently completed. The enrollment target is 14 participants. The study started on 2018-02-19. Estimated completion is 2019-08-12.

What conditions does trial NCT03546803 study?

This clinical trial studies the following conditions: Radiation Dermatitis.

What interventions are being tested in trial NCT03546803?

The interventions under investigation include: 3M™ Cavilon™ Advanced Skin Protectant (OTHER).

Who is sponsoring clinical trial NCT03546803?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03546803 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Radiation Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03546803, the US trial registry maintained by the National Library of Medicine. NCT03546803 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.